Meeting
2021 ASCO Annual Meeting
Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma.
Authors
Caroline Robert
Gustave Roussy and Université Paris-Saclay, Villejuif-Paris, France
Caroline Robert , Karl D. Lewis , Paolo Antonio Ascierto , Rodrigo Ramella Munhoz , Gabriella Liszkay , Luis de la Cruz-Merino , Judit Olah , Paola Queirolo , Jacek Mackiewicz , Ivor Caro , Kalpit Shah , Harper Forbes , Haocheng Li , Christian Hertig , Yibing Yan , Edward Francis Mckenna Jr., Ralf Gutzmer , Grant A. McArthur
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9523)
DOI
10.1200/JCO.2021.39.15_suppl.9523
Abstract #
9523
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma and central nervous system (CNS) metastases (mets).
First Author: Paola Queirolo
Poster
2022 ASCO Annual Meeting
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study.
First Author: Dirk Schadendorf
Poster
2020 ASCO Virtual Scientific Program
Activity and safety of third-line BRAF-targeted therapy (TT) following first-line TT and second-line immunotherapy (IT) in advanced melanoma.
First Author: Victoria Atkinson
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.
First Author: Georgina V. Long